WallStSmart

Edwards Lifesciences Corp (EW)vsSi-Bone Inc (SIBN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 2920% more annual revenue ($6.07B vs $200.93M). EW leads profitability with a 17.7% profit margin vs -9.4%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

SIBN

Avoid

32

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for SIBN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

SIBN1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

SIBN4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$573.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.0%2/10

ROE of -11.0% — below average capital efficiency

Profit MarginProfitability
-9.4%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : SIBN

The strongest argument for SIBN centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : SIBN

The primary concerns for SIBN are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

EW profiles as a mature stock while SIBN is a turnaround play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

SIBN is growing revenue faster at 15.0% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 32/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Si-Bone Inc

HEALTHCARE · MEDICAL DEVICES · USA

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and internationally. The company is headquartered in Santa Clara, California.

Want to dig deeper into these stocks?